Oncogene News and Research

RSS

An oncogene is a gene that, when mutated or expressed at high levels, helps turn a normal cell into a tumor cell.

New $2.3 million NCI grant awarded to Georgia Cancer Center to improve survival of patients with AML

Acute myeloid leukemia (AML) is a cancer that affects blood cells in the bone marrow - the spongy tissue inside certain bones, where new blood cells are made.

17 Apr 2023

Researchers show how the EBV virus exploits genomic weaknesses to cause cancer

The Epstein-Barr virus (EBV) is easily spread through bodily fluids, primarily saliva, such as kissing, shared drinks or using the same eating utensils.

13 Apr 2023

Clinical trial may change the paradigm of care for patients with ALK-driven high-risk neuroblastoma

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

4 Apr 2023

Can the Mediterranean diet and physical exercise improve the quality of life for cancer patients?

Researchers reviewed existing literature on the benefits of adopting Mediterranean diets against inflammatory conditions and cancer.

3 Apr 2023

Notorious oncogene plays a direct role in disguising growing cancers from the immune system

Cancer-associated genes called oncogenes are well known to stimulate cell growth and division — causing tumors to balloon and spread.

28 Mar 2023

Study identifies the essential genetic and immunologic perturbations occurring in patients with long COVID lung fibrosis

Researchers elucidated immunologic and genetic perturbations in long COVID patients with pulmonary fibrosis.

3 Mar 2023

Study finds a new mammalian antiviral response pathway restricting poxviruses replication

In a recent study posted to the bioRxiv* preprint server, researchers identified a novel antiviral pathway different from the interferon (IFN) pathway that inhibited poxvirus(es) replication.

15 Feb 2023

Researchers use multiplexed 3D imaging to perform molecular and morphological assessments of colorectal cancers

Researchers used multiplexed and three-dimensional imaging with machine-based learning and spatial statistics to perform molecular and morphological assessments of colorectal cancers (CRC).

24 Jan 2023

New Pyk2-derived peptide inhibits breast cancer metastasis

An estimated ninety percent of deaths from breast cancer are due to complications resulting from metastasis, a process in which cancer cells break away from where they first formed, travel through the blood or lymph circulatory system, and form new, metastatic tumors in other parts of the body.

17 Jan 2023

New drug combination may offer better prognosis for children diagnosed with deadly brain cancer

Researchers at the University of Colorado Anschutz Medical Campus have discovered a drug combination that may offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.

13 Jan 2023

What is the association between acute lymphoblastic leukemia and congenital cytomegalovirus infection?

Researchers evaluated the relationship between congenital cytomegalovirus (cCMV) infection and acute lymphoblastic leukemia (ALL).

11 Jan 2023

Rare protein variant may hold the key to boosting effectiveness of breast cancer treatment

A rare variant of a protein present in nearly all human cells may hold the key to improving the effectiveness of breast cancer treatment, according to new research funded by Breast Cancer Now.

10 Jan 2023

Insilico announces nomination of preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy

Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy utilizing its end-to-end Pharma.AI platform.

27 Dec 2022

Salk researchers shed new light on specific mechanisms that activate oncogenes

Cancer, caused by abnormal overgrowth of cells, is the second-leading cause of death in the world. Researchers from the Salk Institute have zeroed in on specific mechanisms that activate oncogenes, which are altered genes that can cause normal cells to become cancer cells.

7 Dec 2022

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine's Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.

6 Dec 2022

Study explores practical pathways to motherhood in women with oncogene-driven lung cancer

New research from the University of Colorado (CU) Cancer Center highlights the need for additional data collection for women hoping to have successful pregnancies while undergoing treatment for lung cancer.

5 Dec 2022

Stem cell crosstalk with the microenvironment creates a loop of tumor-promoting factors

What drives tumor growth? Is it a few rogue cells imposing their will upon healthy tissue, or diseased tissue bringing out the worst in otherwise peaceable cells? Or is it a back-and-forth, a dialogue between the two?

30 Nov 2022

Single drug compound may offer a promising new strategy for treating prostate cancer patients

A single drug compound simultaneously attacks hard-to-treat prostate cancer on several fronts, according to a new study in mice and human cells.

23 Nov 2022

Molecular motion of many 'undruggable' proteins reveals previously unseen binding sites

Studying the molecular motion of proteins reveals previously unseen binding sites that could be targeted by new drug candidate molecules.

21 Nov 2022

Researchers receive NIH grant to develop mRNA vaccines to deter cancer development

A multidisciplinary team of Weill Cornell Medicine researchers have received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.

11 Nov 2022